Pharmacology of the GLP-1 analog exenatide extended-release in healthy cats

Exenatide extended-release (ER) is a microencapsulated formulation of the GLP-1-receptor agonist exenatide. It has a protracted pharmacokinetic profile that allows a once-weekly injection with comparable efficacy to insulin with an improved safety profile in type-2 diabetic people. Here we studied the pharmacology of Exenatide-ER in six healthy cats. A single subcutaneous injection of Exenatide-ER (0.13 mg/kg) was administered on day 0. Exenatide concentrations were measured for 12 wk. A hyperglycemic clamp (target = 225 mg/dL) was performed on days -7 (Clamp-I) and 21 (Clamp-II) with measurements of insulin and glucagon concentrations.
Source: Domestic Animal Endocrinology - Category: Endocrinology Authors: Source Type: research